Sigma Planning Corp Acquires New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Share on StockTwits

Sigma Planning Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 1,104 shares of the pharmaceutical company’s stock, valued at approximately $242,000.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in Vertex Pharmaceuticals by 2.6% in the 2nd quarter. BlackRock Inc. now owns 20,708,669 shares of the pharmaceutical company’s stock worth $3,797,554,000 after acquiring an additional 532,371 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Vertex Pharmaceuticals by 1.7% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,242,096 shares of the pharmaceutical company’s stock worth $271,957,000 after acquiring an additional 20,672 shares during the period. Pictet Asset Management Ltd. raised its holdings in Vertex Pharmaceuticals by 2.9% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,169,844 shares of the pharmaceutical company’s stock worth $198,195,000 after acquiring an additional 33,218 shares during the period. Parametric Portfolio Associates LLC raised its holdings in Vertex Pharmaceuticals by 5.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 777,293 shares of the pharmaceutical company’s stock worth $131,689,000 after acquiring an additional 39,435 shares during the period. Finally, TimesSquare Capital Management LLC raised its holdings in Vertex Pharmaceuticals by 20.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 615,220 shares of the pharmaceutical company’s stock worth $104,231,000 after acquiring an additional 105,030 shares during the period. 94.85% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on VRTX. Cowen reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, November 19th. BMO Capital Markets lifted their target price on shares of Vertex Pharmaceuticals from to in a report on Thursday, January 9th. Argus lifted their target price on shares of Vertex Pharmaceuticals to $248.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Maxim Group reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $247.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and twenty have assigned a buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $252.41.

In related news, SVP Paul M. Silva sold 25,630 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $218.92, for a total value of $5,610,919.60. Following the sale, the senior vice president now owns 34,517 shares of the company’s stock, valued at $7,556,461.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $215.00, for a total transaction of $1,075,000.00. Following the completion of the sale, the executive vice president now directly owns 38,416 shares in the company, valued at approximately $8,259,440. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,742 shares of company stock worth $24,453,342. Insiders own 0.70% of the company’s stock.

Shares of NASDAQ:VRTX traded up $3.68 on Friday, hitting $243.77. 22,671 shares of the company were exchanged, compared to its average volume of 1,429,982. The company’s 50 day moving average price is $230.34 and its two-hundred day moving average price is $201.06. Vertex Pharmaceuticals Incorporated has a one year low of $163.68 and a one year high of $249.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.16 and a current ratio of 2.24. The firm has a market capitalization of $61.74 billion, a price-to-earnings ratio of 53.95, a PEG ratio of 1.39 and a beta of 1.45.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, January 30th. The pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.49. Vertex Pharmaceuticals had a net margin of 28.27% and a return on equity of 20.97%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $1.30 EPS. The business’s revenue was up 62.4% compared to the same quarter last year. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 6.45 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Recommended Story: Growth Stocks

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.